The agreement is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026. Akums already has 2 of its sites (injectable and oral solids) approved by European Regulators. The composite value of the agreement is approximately Euro 200 million (Rs 1,760 crore approx). Akums group, against this agreement, will receive an upfront payment for product development and site approval from European authorities. The project has been secured with an upfront payment of Euro 100 million (Rs 880 crore). Sanjeev Jain, managing director (MD) of Akums added 'It gives us immense pleasure to enter in a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma company. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.' Sandeep Jain, MD of Akums added 'These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world class R&D capabilities. With this, we will add one more dosage form in our portfolio, can be offered in European market. Akums already has European approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye-drops and dry powder injection.' Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

This collaboration exclusively focuses on aseptic manufacturing and subsequent filling in carton packing for the ready-to-drink (RTD) market, targeting an expansive array of health and wellness products. The electrolyte RTD market in India, valued at over Rs 1,000 crore with more than 150 million packs sold annually, is experiencing robust growth. With a steady 10% annual increase in volume, this market sees heightened demand, particularly during the summer months, when hydration needs peak. Simultaneously, the broader Indian RTD market is witnessing significant expansion, driven by a rising preference for functional beverages, therapeutic drinks, and wellness products. Aseptic carton packing technology is at the forefront of this evolution. It ensures the highest standards of safety, shelf stability, and nutrient retention, meeting the evolving needs of modern consumers. Sanjeev Jain, managing director of Akums Drugs & Pharmaceuticals, said: 'With this partnership, Akums and Jagdale will deliver products that seamlessly integrate health benefits with superior Aseptic packaging technology.' Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY24. The scrip shed 0.98% to currently trade at Rs 665.80 on the BSE. Powered by Capital Market - Live

Under the agreement, Akums was granted exclusive rights to sell a selection of Caregen's products in India for the duration of the partnership. The company would also be responsible for the packaging, marketing, and selling of Caregen's bulk products under either Caregen's trademark, Akums' trademark, or Akums' clients' trademarks. Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY245.Powered by Capital Market - Live

Net profit of Akums Drugs & Pharmaceuticals rose 105.00% to Rs 65.21 crore in the quarter ended September 2024 as against Rs 31.81 crore during the previous quarter ended September 2023. Sales declined 12.54% to Rs 1033.09 crore in the quarter ended September 2024 as against Rs 1181.25 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1033.091181.25 -13 OPM %11.7312.85 - PBDT122.75144.95 -15 PBT87.89114.53 -23 NP65.2131.81 105 Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals has entered into a License & Distribution Agreement with Triple Hair Inc, a company duly incorporated under the laws of New Brunswick, Canada, having its registered office at 5085 Principale-Est Av, Dieppe, New Brunswick, Canada. As per the terms of the agreement, Company has been granted the exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India. The Company will undertake this development and commercialization after obtaining the necessary regulatory approvals or requisite licenses in India. The agreement grants the Company exclusive right to use Triple Hair's intellectual property rights (Patent) solely to carry out the studies and perform the services as stipulated in the agreement. Further, Company will manage the commercial strategy to promote and offer Triple Hair's patented products to its own marketing partners and clients within the Indian market exclusively. Powered by Capital Market - Live

Revenue from operations was at Rs 1,019 crore in the quarter ended 30 June 2024, up 5.06% as against with Rs 969.89 crore posted in corresponding quarter last year. Profit before tax stood at Rs 87.47 crore in Q1 FY25 as compared pre tax loss of Rs 158.79 crore reported in Q1 FY24. The firm reported quarterly EBITDA of Rs 130.70 crore in Q1 FY25, registering a growth of 21.01% year on year. EBITDA margin improved to 12.7% in Q1 FY25 as compared to 11% recorded in the corresponding quarter previous year. The company's revenue from CMDO business was at Rs 782 crore in Q1 FY25, up 5.60% as against with Rs 740.50 crore posted in Q1 FY24. This was driven by strong growth in sales volume of 13.9%. Branded and generic formulations segment revenue stood at Rs 167.40 crore during the quarter, marking a de-growth of 12.49% year on year basis. The API segment revenue jumped 82.46% to Rs 69.70 crore in Q1 FY25 as against with Rs 38.20 crore posted in the corresponding quarter previous year. As on 30 June 2024, debt to equity improved to 0.25 times with Net debt at Rs 212.80 crore. Commenting on the financial performance, Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals, stated, 'Our Q1 results show our ongoing efforts to optimize our operations and capitalise on our strengths in the CDMO segment. We are committed to driving sustainable growth across all our business segments and delivering value to our stakeholders.' Meanwhile, the company's board announced the new Injectable facility housed in Akums Healthcare started commercial production on 22 August 2024, with a capacity of 362 million units annually. Akums already has a significant presence in injectable CDMO space and this new facility is expected to consolidate its leadership position in Indian CDMO market. Further, the board of directors, approved a plan to set up two production facilities in Jammu at an overall investment of Rs 265 crore. These will be multi-dosage facilities across pharmaceutical and nutraceutical products. Speaking on the company's plans, Sandeep Jain, MD, Akums Drugs & Pharmaceuticals, said, 'The launch of our injectable facility and the Jammu expansion are key steps in our strategy to enhance our production capabilities. These developments, coupled with our ongoing efforts in R&D and innovation, are aligned with our endeavour to respond effectively to the evolving demands of our clients and the healthcare industry.' Lastly, the company's board appointment Amrut Medhekar as a Chief Executive Officer, CDMO business with effect from 24 August, 2024. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The script slipped 2.97% to currently trade at Rs 913.05 on the BSE.Powered by Capital Market - Live

Net profit of Akums Drugs & Pharmaceuticals reported to Rs 60.17 crore in the quarter ended June 2024 as against net loss of Rs 188.23 crore during the previous quarter ended June 2023. Sales rose 5.07% to Rs 1019.11 crore in the quarter ended June 2024 as against Rs 969.89 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1019.11969.89 5 OPM %12.56-12.92 - PBDT121.54-129.33 LP PBT87.48-159.04 LP NP60.17-188.23 LP Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 August 2024.Powered by Capital Market - Live